According to a new report, published by KBV research, The Global Sickle Cell Disease Treatment Market size is expected to reach $7.3 billion by 2030, rising at a market growth of 27.9% CAGR during the forecast period.
The Blood Transfusion segment is leading the Global Sickle Cell Disease Treatment Market by Treatment in 2022; thereby, achieving a market value of $3.6 billion by 2030. The segment share has expanded dramatically due to factors such as a high adoption rate, the scarcity of alternative treatment choices, rising blood donations globally, and the efficiency of the blood transfusion method. In addition, private and government organizations' participation in blood donation programs meets the demand for blood transfusions for the treatment of sickle cell disease.
The Specialty Clinics segment would showcase a CAGR of 28.1% during (2023 - 2030). Growing utilization of therapeutic drugs for the management of sickle cell disease and rising approval of new drugs are expected to drive the expansion of the segment over the forecast period. Specialty clinics offer the convenience of consulting and advanced clinic facilities, which are beneficial aspects for many customers.
The North America region dominated the Global Sickle Cell Disease Treatment Market by Region in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $2.7 billion by 2030. The Europe market is anticipated to grow at a CAGR of 27.4% during (2023 - 2030). Additionally, The Asia Pacific market would witness a CAGR of 28.8% during (2023 - 2030).
Full Report: https://www.kbvresearch.com/sickle-cell-disease-treatment-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country-wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Novartis AG, Pfizer Inc., bluebird bio, Inc., CSL Limited, Emmaus Life Sciences, Inc., Bristol Myers Squibb Company, CRISPR Therapeutics AG, Agios Pharmaceuticals, Inc. (LES LABORATOIRES SERVIER SAS), Novo Nordisk A/S and Medunik USA (Duchesnay Inc.)
By Treatment
By End-Use
By Geography
Companies Profiled
Unique Offerings 
